Impact of acute rejection therapy on infections and malignancies in renal transplant recipients
Impact of acute rejection therapy on infections and malignancies in renal transplant recipients
复制标题
DOI：
10.1097/00007890-199911270-00027
复制
发表时间：
1999-11-27
期刊：
影响因子：
6.2
通讯作者：
Walker, RG
中科院分区：
文献类型：
--
作者：
Jamil, B;Nicholls, K;Walker, RG
背景。感染和恶性肿瘤是同种异体肾移植受者死亡和发病的重要原因。他们的风险随着免疫抑制的增加而增加。方法。为了量化与抗排斥治疗相关的这些并发症风险的增加，我们回顾了我们中心在环孢菌素时代移植的所有同种异体肾移植受者的记录。根据移植后前 6 个月内的急性排斥反应情况以及急性排斥反应的治疗情况，我们将患者分为三组：未发生 AR 组 1 的患者（n=168）；未发生 AR 组的患者（n=168）；发生过一次或多次急性排斥反应并接受高剂量皮质类固醇治疗的患者——第 2 组（n=169）；除皮质类固醇外还需要细胞溶解剂 (OKT3) 和/或其他药物组 3 的患者 (n=141)。结果。第 1 组中 52% 的患者、第 2 组中 71% 的患者和第 3 组中 86% 的患者在移植后的前 6 个月内发生过一次或多次感染。第 2 组和第 3 组的相对风险分别为 1.56 (P=0.0002) 和 2.98 (P
Background. Infections and malignancies are important causes of mortality and morbidity in renal allograft recipients. Their risk increases with increasing immunosuppression.Methods. In an attempt to quantitate the increase in the risk of these complications in association with antirejection therapy, we reviewed the records of all renal allograft recipients of our center transplanted during the cyclosporin era. We sub-divided the patients into three groups based on acute rejection episodes during the first 6 months posttransplant, and the treatment for acute rejection: those who did not develop AR-group 1 (n=168); those who had one or more episodes of acute rejection and were treated with high dose corticosteroids -group 2 (n=169); those who in addition to corticosteroids required cytolytics (OKT3,) and/or other drugs-group 3 (n=141).Results. 52% patients in group 1, 71% patients in group 2 and 86% patients in group 3 had one or more episodes of infection during the first 6 months posttransplantation. Relative risk for group 2 and 3 were 1.56 (P=0.0002) and 2.98 (P